ABSTRACT:
For the purpose of determining the presence of Tadalafil in spiked human plasma, a precise, user-friendly, and repeatable RP-HPLC technique remained created & verified using Sildenafil as an internal reference. The Cromasil C18(250mmx 4.6 ID, particle size:5 micron) column remained used to complete a chromatographic partition. The mobile phase used was methanol: water in a ratio of 15:85% v/v, at pH 2.5.0, with a binary gradient system maintaining a flow rate of 0.8ml/min. The drug sample’s discovery wavelength was 284nm. Ethyl acetate was used as the extracting solvent in the extraction process. It was discovered that Tadalafil has a retention time of 3.7 minutes. It was discovered that the procedure was liner within the concentraion series of 0.4-6.4ug/ml. The value of the lmit of quatation was discovered to 0.69. The precision and accuracy within the selected range are both intra- and inter-day. It was shown that the recovery studies ranged from 98.6 to 100.2%. It was discovered that the RSD ranged from 0.06-2.50%. The results showed that all parameters from the tampered human plasma were valid. The suggested RP-HPLC approach can be used for therapeutic medication monitoring and pharmacokinetic investigations. It is very quick and accurate at determining the presence of Tadalafil in human plasma.
Cite this article:
Mayur S. Jain, Shailesh K. Koradia. RP-HPLC-Based Bioananalytical Method Development and Validation for Tadalafil Identification in Spiked Human Plasma. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):85-0. doi: 10.52711/2231-5675.2025.00014
Cite(Electronic):
Mayur S. Jain, Shailesh K. Koradia. RP-HPLC-Based Bioananalytical Method Development and Validation for Tadalafil Identification in Spiked Human Plasma. Asian Journal of Pharmaceutical Analysis. 2025; 15(2):85-0. doi: 10.52711/2231-5675.2025.00014 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-2-3
REFERENCES:
1. Kuan J, Brock G. Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2002; 11:1605–1613.
2. Meuleman EJ. Review of tadalafil in the treatment of erectile dysfunction. Expert Opin Pharmacother. 2003; 4:2049–2056.
3. Corbin JD. Mechanisms of action of PDE5 inhibition in erectile dysfunction. Int J Impot Res. 2004;16(Suppl 1): S4–S7.
4. Cheng CL, Chou CH. Determination of tadalafil in small volumes of plasma by high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2005; 822:278–284.
5. Shakya AK, Abu-awwad AN, Arafat TA, Melhim M. Validated liquid chromatographic-ultraviolet method for the quantitation of tadalafil in human plasma using liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 852:403–408.
6. Webb, D.J.; Freestone, S.; Allen, M.J.; Muirhead, G.J. (March 4, 1999). "Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist". Am. J. Cardiol. 83 (5A): 21C–28C. doi:10.1016/S0002-9149(99)00044-2. PMID 10078539
7. The Journal of Urology, Volume 177, Issue 3, Pages 1071-1077 K. McVary, W. Monnig, J. Camps Jr., J. Young, L. Tseng, G. van den Ende.
8. J. D. Corbin and S. H. Sharron. "Molecular Biology and Pharmacology of PDE-5-Inhibitor Therapy for Erectile Dysfunction". J. Androl. 24: S38-S41.
9. J. D. Corbin and S. H. Sharron. "Molecular Biology and Pharmacology of PDE-5-Inhibitor Therapy for Erectile Dysfunction". J. Androl. 24: S38-S41.
10. C. Ho and G.L. Chen, stability indicating HPLC Assay methods for Drug in Pharmaceutical dosage forms: Part-I, J Food Drug Anal.4(1996)271-292.
11. Samuel R. Gartz. PhD. E.D. Drugs and analogs; Characterization of phosphodiesterase- 5 Inhibitors in suspect couterfeit and herbal products. USP Annual Scientific Meeting. 2007.